CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today reported preliminary data on secondary endpoints from its CLASSIC II investigational study examining the safety and effectiveness of Clolar® (clofarabine) as a single agent to treat high-risk adult patients with acute myeloid leukemia (AML). This information was presented this afternoon at the 50th Annual Meeting of the American Society of Hematology.
